A number of research firms have changed their ratings and price targets for Novo Nordisk A/S (NYSE: NVO):

  • 9/17/2016 – Novo Nordisk A/S was given a new $57.00 price target on by analysts at Bank of America Corp.. They now have a “hold” rating on the stock.
  • 9/14/2016 – Novo Nordisk A/S had its “hold” rating reaffirmed by analysts at Jefferies Group.
  • 9/13/2016 – Novo Nordisk A/S was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Novo Nordisk has a strong presence in the diabetes care market. Additionally, products like Victoza and Tresiba along with contributions from Saxenda and Xultophy are expected to continue boosting the top line. We are encouraged by the company’s efforts to develop its pipeline candidates. Although the company expects modern insulins and new launches to continue performing well, headwinds will come in the form of a contract loss in the U.S., healthcare reforms, intensifying competition within the diabetes and biopharmaceuticals markets, and macroeconomic conditions in many international markets. We remain concerned about the company’s insulin product prices that are either subsidized or are subject to price control. Patent expiration issues faced by several products in Novo Nordisk’s portfolio are also concerning.”
  • 9/13/2016 – Novo Nordisk A/S was upgraded by analysts at Pacific Crest from a “neutral” rating to an “outperform” rating.
  • 9/13/2016 – Novo Nordisk A/S was upgraded by analysts at BNP Paribas from a “neutral” rating to an “outperform” rating.
  • 9/12/2016 – Novo Nordisk A/S was upgraded by analysts at Deutsche Bank AG from a “hold” rating to a “buy” rating.
  • 9/9/2016 – Novo Nordisk A/S was downgraded by analysts at JPMorgan Chase & Co. from an “overweight” rating to a “neutral” rating.
  • 9/6/2016 – Novo Nordisk A/S was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Novo Nordisk received a setback with the extension of the regulatory review period of its New Drug Application of IDegLira for the treatment of adults with type II diabetes. A response from the FDA is now expected in Dec 2016. The company expects modern insulins and new launches to continue performing well although headwinds will come from contract loss in the U.S., healthcare reforms, intensifying competition within the diabetes and biopharmaceuticals markets, and unfavorable macroeconomic conditions in many international markets. We remain concerned about the company’s insulin product prices that are either subsidized or are subject to price control. Patent expiration issues faced by several products in Novo Nordisk’s portfolio are also concerning. Nevertheless, we are positive on the company’s strong presence in the diabetes care market.”
  • 9/1/2016 – Novo Nordisk A/S was downgraded by analysts at Morgan Stanley from an “overweight” rating to an “equal weight” rating.
  • 8/31/2016 – Novo Nordisk A/S was upgraded by analysts at HSBC from a “reduce” rating to a “hold” rating.
  • 8/8/2016 – Novo Nordisk A/S was downgraded by analysts at Bank of America Corp. from a “buy” rating to a “neutral” rating.
  • 8/3/2016 – Novo Nordisk A/S had its “buy” rating reaffirmed by analysts at Citigroup Inc..

Shares of Novo Nordisk A/S (NYSE:NVO) traded down 0.41% during trading on Wednesday, reaching $46.04. The company’s stock had a trading volume of 2,530,766 shares. Novo Nordisk A/S has a 12-month low of $44.04 and a 12-month high of $59.00. The stock’s 50-day moving average is $47.40 and its 200-day moving average is $53.09. The stock has a market cap of $116.77 billion, a P/E ratio of 21.64 and a beta of 0.74.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/novo-nordisk-as-nvo-research-analysts-recent-ratings-changes.html

The business also recently declared a dividend, which was paid on Tuesday, August 23rd. Stockholders of record on Monday, August 15th were given a $0.326 dividend. The ex-dividend date was Thursday, August 11th. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 48.82%.

Novo Nordisk A/S is a healthcare company. The Company is engaged in discovery, development, manufacturing and marketing of pharmaceutical products. The Company’s business segments include diabetes and obesity care, and biopharmaceuticals. The diabetes and obesity care segment covers insulins, glucagon-like peptide-1 (GLP-1), other protein-related products (such as glucagon, protein-related delivery systems and needles), oral anti-diabetic drugs and obesity.

5 Day Chart for NYSE:NVO

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.